In analyses stratified by the presence of cognitive impairment, p-tau biomarkers were much more strongly associated with amyloid PET in CU individuals, whereas no differences were detected in cognitively impaired individuals (eTables 3 and 4 in the Supplement). The gene discussed is MAPT; the disease is Cognitive impairment.